Arissa Young, MD
- Rheumatology
About
Dr. Young is a physician-scientist in the Division of Rheumatology at UCLA who specializes in systemic sclerosis and connective tissue disease–associated interstitial lung disease (CTD-ILD). She cares for patients with complex autoimmune rheumatic diseases, particularly those with lung and skin involvement.
Dr. Young completed fellowship training in Rheumatology followed by advanced fellowship training in connective tissue disease–associated interstitial lung disease. She is part of the UCLA Specialty Training and Advanced Research (STAR) Program, which supports the development of physician-scientists pursuing translational research.
Her research focuses on the mechanisms driving skin and lung fibrosis in systemic sclerosis, with the goal of identifying pathways that contribute to disease progression and developing new therapies.
Outside of work, she enjoys spending time with her children and traveling.
Languages
Education
Medical Board Certifications
Fellowship
Residency
Degrees
Locations
Medical Services
Areas of Focus
Research
Interests
Systemic sclerosis, fibrosis, metabolomics, microbiome
Publications
Young A, Weltzien E, Kwan M, Castillo A, Caan B, Kroenke CH. Pre- to post-diagnosis weight change and associations with physical functional limitations in breast cancer survivors. J Cancer Surviv. 2014 Dec;8(4):539-47.
Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB. Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist. 2019 May;24(5):584-588.
Young AC, Quach HT, Song H, Davis EJ, Moslehi JJ, Ye F, Williams GR, Johnson DB. Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma. J Immunother Cancer. 2020 Jul;8(2):e00082.
Patrinely JR Jr, Young AC, Quach H, Williams GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman JA, Friedman DL, Moslehi JJ, Johnson DB. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer. 2020 Aug;135:211-220.
Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, Blank CU, Sandhu S, Carlino MS, Larkin JMG, Menzies AM, Long GV. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Ann Oncol. 2020 Aug;31(8):1075-1082.
Sugiura A, Andrejeva G, Voss K, Heintzman DR, Xu X, Madden MZ, Ye X, Beier KL, Chowdhury NU, Wolf MM, Young AC, Greenwood DL, Sewell AE, Shahi SK, Freedman SN, Cameron AM, Foerch P, Bourne T, Garcia-Canaveras JC, Karijolich J, Newcomb DC, Mangalam AK, Rabinowitz JD, Rathmell JC. MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. Immunity. 2022 Jan 11;55(1):65-81.e9.
Voss K, Sewell AE, Krystofiak ES, Gibson-Corley KN, Young AC, Basham JH, Sugiura A, Arner EN, Beavers WN, Kunkle DE, Dickson ME, Needle GA, Skaar EP, Rathmell WK, Ormseth MJ, Major AS, Rathmell JC. Elevated transferrin receptor impairs T cell metabolism and function in systemic lupus erythematosus. Sci Immunol. 2023 Jan 13;8(79):eabq0178.
Steiner KK, Young AC, Patterson AR, Sugiura A, Watson MJ, Preston SEJ, Zhelonkin A, Jennings EQ, Chi C, Heintzman DR, Pahnke AP, Toudji YT, Hatem Z, Madden MZ, Arner EN, Sewell AE, Blount AK, Okparaugo R, Fallman E, Krystofiak ES, Sheldon RD, Gibson-Corley KN, Voss K, Nowinski SM, Jones RG, Mogilenko DA, Rathmell JC. Mitochondrial fatty acid synthesis and MECR regulate CD4+ T cell function and oxidative metabolism. J Immunol. 2025 May 1;214(5):958-976.
Andréasson, K., Young, A., Joshi, S., Labus, J. S., Low, A. H. L., Smith, V., McMahan, Z., Proudman, S., Valenzuela, A., Hunter, P., Kim, G. H., Bozovic, G., Goldin, J., Aja, E., Jacobs, J. P., & Volkmann, E. R. (2025). International Investigation of the Gut‐Lung Axis in Systemic Sclerosis‐Interstitial Lung Disease. Arthritis Care & Research. https://doi.org/10.1002/acr.25623
Young, A. C., Andréasson, K., Labus, J., Matulionis, N., Jacobs, J. P., Christofk, H., & Volkmann, E. R. (2025). Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis. ACR Open Rheumatology, 7(11). https://doi.org/10.1002/acr2.70127
Lee JY, Mahurkar-Joshi S, Young A, Labus JS, He B, Aja E, Jacobs JP, Volkmann ER. Ultra-processed food intake is associated with increased gastrointestinal tract symptoms and alterations in gut microbiota in patients with systemic sclerosis. Front Immunol. 2025 Oct 9;16:1610360. doi: 10.3389/fimmu.2025.1610360. PMID: 41142817; PMCID: PMC12546150.
In the News
Insurance
- Aetna
- Anthem Blue Cross
- Blue Shield of California
- Centivo
- Cigna
- First Health
- Health Net of California
- Interplan (part of HealthSmart)
- Medicare Advantage
- MultiPlan
- UFCM Health System
- Prime Health Services
- Private Healthcare Systems (PHCS)
- TRICARE
- UnitedHealthcare
The list of health care plans above may not be comprehensive and could change.
Please contact your benefits coordinator or health insurance company directly to verify coverage.
Visit our health insurance information page for more details.
Recognitions
2016 Alpha Omega Alpha Honor Medical Society
2017 Louis Weinstein Award
2017 AMWA Award
2023 Suzanne Eaton PhD Memorial Prize
2024 National Institutes of Health Loan Repayment Award
2025 American College of Rheumatology Distinguished Fellow Award
2025 Bevra Hahn, MD Rheumatology Fellowship Award
Links
https://sites.libsyn.com/436041/fecal-metabolome-in-early-systemic-sclerosis